Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Sep;93(9):1037-46.
doi: 10.1111/j.1349-7006.2002.tb02481.x.

Reversal of P-glycoprotein-mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line

Affiliations

Reversal of P-glycoprotein-mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line

Hideki Enokida et al. Jpn J Cancer Res. 2002 Sep.

Abstract

We isolated a paclitaxel-resistant cell line (KK47/TX30) from a human bladder cancer cell line (KK47/WT) in order to investigate the mechanism of and reversal agents for paclitaxel resistance. KK47/TX30 cells exhibited 700-fold resistance to paclitaxel and cross-resistance to vinca alkaloids and topoisomerase II inhibitors. Tubulin polymerization assay showed no significant difference in the ratio of polymerized alpha- and beta-tubulin between KK47/WT and KK47/TX30 cells. Western blot analysis demonstrated overexpression of P-glycoprotein (P-gp) and lung resistance-related protein (LRP) in KK47/TX30 cells. Drug accumulation and efflux studies showed that the decreased paclitaxel accumulation in KK47/TX30 cells was due to enhanced paclitaxel efflux. Cell survival assay revealed that verapamil and cepharanthine, conventional P-gp modulators, could completely overcome paclitaxel resistance. To investigate whether new synthetic isoprenoids could overcome paclitaxel resistance, we synthesized 31 isoprenoids based on the structure of N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine (SDB), which could reverse multidrug resistance (MDR), as shown previously. Among those examined, trans-N,N'-bis(3,4-dimethoxybenzyl)-N-solanesyl-1,2-diaminocyclohexane (N-5228) could completely reverse paclitaxel resistance in KK47/TX30 cells. N-5228 inhibited photoaffinity labeling of P-gp by [(3)H]azidopine, suggesting that N-5228 could bind to P-gp directly and could be a substrate of P-gp. Next, we investigated structural features of these 31 isoprenoids in order to determine the structural requirements for the reversal of P-gp-mediated paclitaxel resistance, suggesting that the following structural features are important for overcoming paclitaxel resistance: (1) a basic structure of 8 to 10 isoprene units, (2) a cyclohexane ring or benzene ring within the framework, (3) two cationic sites in close proximity to each other, and (4) a benzyl group with 3,4-dimethoxy functionalities, which have moderate electron-donating ability. These findings may provide valuable information for the development of P-gp-mediated MDR-reversing agents.

PubMed Disclaimer

Similar articles

Cited by

References

    1. ) Bremnes , R. M. , Sundstrom , S. , Vilsvik , J. and Aasebo , U.Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited‐stage small‐cell lung cancer . J. Clin. Oncol. , 19 , 3532 – 3538 ( 2001. ). - PubMed
    1. ) Riccardi , A. , Pugliese , P. , Danova , M. , Brugnatelli , S. , Grasso , D. , Giordano , M. , Bernardo , G. , Giardina , G. , Fava , S. , Montanari , G. , Pedrotti , C. , Trotti , G. , Rinaldi , E. , Poli , M. A. and Tinelli , C.A phase II study of sequential 5‐fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01) . Br. J. Cancer , 85 , 141 – 146 ( 2001. ). - PMC - PubMed
    1. ) Prince , H. M. , Rischin , D. , Quinn , M. , Allen , D. , Planner , R. , Neesham , D. , Gates , P. and Davison , J.Repetitive high‐dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study . Gynecol. Oncol. , 81 , 216 – 224 ( 2001. ). - PubMed
    1. ) Hurwitz , C. A. , Strauss , L. C. , Kepner , J. , Kretschmar , C. , Harris , M. B. , Friedman , H. , Kun , L. and Kadota , R.Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study . J. Pediatr. Hematol. Oncol. , 23 , 277 – 281 ( 2001. ). - PubMed
    1. ) Haas , N. , Roth , B. , Garay , C. , Yeslow , G. , Entmacher , M. , Weinstein , A. , Rogatko , A. , Babb , J. , Minnitti , C. , Flinker , D. , Gillon , T. and Hudes , G.Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone‐refractory prostate cancer . Urology , 58 , 59 – 64 ( 2001. ). - PubMed

MeSH terms